Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3 trial, joining two others that are already in phase 3 development.
Metric
Q3 2017
Source: Fool.com
Alnylam Pharmace. Stock
€189.65
0.350%
With 50 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 426 € there is potential for a 124.62% increase which would mean more than doubling the current price of 189.65 € for Alnylam Pharmace..
